Fukao, T. & Nakamura, Okay. Advances in inborn errors of metabolism. J. Hum. Genet. 64, 65 (2019).
Boyer, S. W., Barclay, L. J. & Burrage, L. C. Inherited metabolic problems: Facets of persistent dietary administration. Nutr. Clin. Pract. 30, 502 (2015).
Ranganath, L. R., Jarvis, J. C. & Gallagher, J. A. Current advances in administration of alkaptonuria (invited evaluation; greatest observe article). J. Clin. Pathol. 66, 367–373 (2013).
Gallagher, J. A., Dillon, J. P., Sireau, N., Timmis, O. & Ranganath, L. R. Alkaptonuria: An instance of a ‘basic illness’-A uncommon illness with vital classes for extra widespread problems. Semin. Cell Dev. Biol. 52, 53–57 (2016).
Saudubray, J.-M., van den Berghe, G. & Walter, J. H. Inborn metabolic illnesses analysis and remedy. Inborn Metabolic Ailments: Analysis and Therapy (Springer-Verlag Berlin Heidelberg, 2012). https://doi.org/10.1007/978-3-642-15720-2.
Suwannarat, P. et al. Use of nitisinone in sufferers with alkaptonuria. Metabolism 54, 719–728 (2005).
Hughes, J. H. et al. Conditional focusing on in mice reveals that hepatic homogentisate 1,2-dioxygenase exercise is crucial in decreasing circulating homogentisic acid and for efficient remedy within the genetic illness alkaptonuria. Hum. Mol. Genet. 28, 3928–3939 (2019).
Neuckermans, J., Mertens, A., De Win, D., Schwaneberg, U. & De Kock, J. A strong bacterial assay for high-throughput screening of human 4-hydroxyphenylpyruvate dioxygenase inhibitors. Sci. Rep. 9, 1–11 (2019).
Lock, E., Ranganath, L. R. & Timmis, O. The position of nitisinone in tyrosine pathway problems. Curr. Rheumatol. Rep. 16, 1–8 (2014).
Ranganath, L. R. et al. Suitability of nitisinone In alkaptonuria 1 (SONIA 1): A world, multicentre, randomised, open-label, no-treatment managed, parallel-group, dose-response examine to research the impact of as soon as day by day nitisinone on 24-h urinary homogentisic acid excretion in sufferers with alkaptonuria after 4 weeks of remedy. Ann. Rheum. Dis. 75, 362–367 (2016).
Nemethova, M. et al. Twelve novel HGD gene variants recognized in 99 alkaptonuria sufferers: Deal with ‘black bone illness’ in Italy. Eur. J. Hum. Genet. 24, 66–72 (2015).
Helliwell, T. R., Gallagher, J. A. & Ranganath, L. Alkaptonuria—A evaluation of surgical and post-mortem pathology. Histopathology 53, 503–512 (2008).
Ranganath, L. R. et al. Nitisinone arrests ochronosis and reduces charge of development of alkaptonuria: Analysis of the impact of nitisinone in the UK nationwide alkaptonuria centre. Mol. Genet. Metab. 125, 127–134 (2018).
Zatkova, A., Ranganath, L. & Kadasi, L. Alkaptonuria: Present views. Appl. Clin. Genet. 13, 37–47 (2020).
Spiga, O. et al. A brand new built-in and interactive instrument relevant to inborn errors of metabolism: Utility to alkaptonuria. Comput. Biol. Med. 103, 1–7 (2018).
Spiga, O., Cicaloni, V., Bernini, A., Zatkova, A. & Santucci, A. ApreciseKUre: An strategy of precision drugs in a uncommon illness. BMC Med. Inform. Decis. Mak. 17, 42 (2017).
Zatkova, A. An replace on molecular genetics of Alkaptonuria (AKU). J. Inherit. Metab. Dis. 34, 1127–1136 (2011).
Al-Sbou, M., Mwafi, N. & Lubad, M. A. Identification of forty circumstances with alkaptonuria in a single village in Jordan. Rheumatol. Int. 32, 3737–3740 (2012).
Al-sbou, M. Novel mutations within the homogentisate 1,2 dioxygenase gene recognized in Jordanian sufferers with alkaptonuria. Rheumatol. Int. 32, 1741–1746 (2011).
Al-Sbou, M. & Mwafi, N. 9 circumstances of alkaptonuria in a single household in southern Jordan. Rheumatol. Int. 32, 621–625 (2012).
Sakthivel, S. et al. Mutation screening of the HGD gene identifies a novel alkaptonuria mutation with vital founder impact and excessive prevalence. Ann. Hum. Genet. 78, 155–164 (2014).
Zatková, A. et al. Excessive frequency of alkaptonuria in Slovakia: Proof for the looks of a number of mutations in HGO involving totally different mutational scorching spots. Am. J. Hum. Genet. 67, 1333 (2000).
Srsen, S. & Varga, F. Screening for alkaptonuria within the new child in Slovakia. Lancet 2, 576 (1978).
Ranganath, L. R. et al. Efficacy and security of once-daily nitisinone for sufferers with alkaptonuria (SONIA 2): A world, multicentre, open-label, randomised managed trial. Lancet Diabetes Endocrinol. 8, 762–772 (2020).
Ascher, D. B. et al. Homogentisate 1,2-dioxygenase (HGD) gene variants, their evaluation and genotype–phenotype correlations within the largest cohort of sufferers with AKU. Eur. J. Hum. Genet. 27, 888–902 (2019).
White, A. & Tchan, C. M. Nitisinone-induced keratopathy in alkaptonuria: A difficult analysis regardless of medical suspicion. JIMD Rep. 40, 7–9 (2018).
Khedr, M. et al. Asymptomatic corneal keratopathy secondary to hypertyrosinaemia following low dose nitisinone and a literature evaluation of tyrosine keratopathy in alkaptonuria. JIMD Rep. 40, 31–37 (2018).
Hughes, J. H. et al. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia related to nitisinone remedy of alkaptonuria. J. Inherit. Metab. Dis. 43, 259–268 (2020).
Thimm, E. et al. Neurocognitive end result in sufferers with hypertyrosinemia sort i after long-term remedy with NTBC. J. Inherit. Metab. Dis. 35, 263–268 (2012).
Khedr, M. et al. Nitisinone causes acquired tyrosinosis in alkaptonuria. J. Inherit. Metab. Dis. 43, 1014–1023 (2020).
Davison, A. S. et al. Evaluation of the impact of as soon as day by day nitisinone remedy on 24-h urinary metadrenalines and 5-hydroxyindole acetic acid excretion in sufferers with alkaptonuria after 4 weeks of remedy. JIMD Rep. 41, 1–10 (2018).
Garrod, A. E. The incidence of alkaptonuria: A examine in chemical individuality. Yale J. Biol. Med. 75, 221–231 (2002).
La Du, B. N., Zannoni, V. G., Laster, L. & Seegmiller, J. E. The character of the defect in tyrosine metabolism in alcaptonuria. J. Biol. Chem. 230, 251–260 (1958).
Fernândez-Canon, J. M. et al. The molecular foundation of alkaptonuria. Nat. Genet. 14, 19–24 (1996).
Bernini, A. et al. Towards a generalized computational workflow for exploiting transient pockets as new targets for small molecule stabilizers: Utility to the homogentisate 1,2-dioxygenase mutants on the base of uncommon illness alkaptonuria. Comput. Biol. Chem. 70, 133–141 (2017).
HGD homepage–HGD mutation database–Leiden open variation database. Out there at: http://hgddatabase.cvtisr.sk/residence.php?select_db=HGD. Accessed: nineteenth April 2022.
Karmakar, M. et al. HGDiscovery: A web-based instrument offering practical and phenotypic info on novel variants of homogentisate 1,2- dioxigenase. bioRxiv https://doi.org/10.1101/2021.04.26.441386 (2021).
Jia, B. & Jeon, C. O. Excessive-throughput recombinant protein expression in Escherichia coli: Present standing and future views. Open Biol. 6, 160–196 (2016).
Rosano, G. L. & Ceccarelli, E. A. Recombinant protein expression in Escherichia coli: Advances and challenges. Entrance. Microbiol. 5, 1–17 (2014).
Rodríguez, J. M. et al. Structural and practical evaluation of mutations in alkaptonuria. Hum. Mol. Genet. 9, 2341–2350 (2000).
Matalonga, L., Gort, L. & Ribes, A. Small molecules as therapeutic brokers for inborn errors of metabolism. J. Inherit. Metab. Dis. 40, 177–193 (2017).
Hou, Z. S., Ulloa-Aguirre, A. & Tao, Y. X. Pharmacoperone medication: focusing on misfolded proteins inflicting lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational problems. Professional Rev. Clin. Pharmacol. 11, 611–624 (2018).
Aymami, J., Barril, X., Rodríguez-Pascau, L. & Martinell, M. Pharmacological chaperones for enzyme enhancement remedy in genetic illnesses. Pharm. Pat. Anal. 2, 109–124 (2013).
Iversen, P. W. et al. Assay Steering Guide. HTS Assay Validation (Eli Lilly & Firm and the Nationwide Middle for Advancing Translational Sciences, 2004).
Tee, Okay. L. & Schwaneberg, U. A screening system for the directed evolution of epoxygenases: Significance of place 184 in P450 BM3 for stereoselective styrene epoxidation. Angew. Chemie Int. Ed. 45, 5380–5383 (2006).
Islam, S., Mate, D. M., Martínez, R., Jakob, F. & Schwaneberg, U. A strong protocol for directed aryl sulfotransferase evolution towards the carbohydrate constructing block GlcNAc. Biotechnol. Bioeng. 115, 1106–1115 (2018).
Garrod, A. E. The croonian lectures on inborn errors of metabolism. Lancet 172, 1–7 (1908).
Amaya, A. A., Brzezinski, Okay. T., Farrington, N. & Moran, G. R. Kinetic evaluation of human homogentisate 1,2-dioxygenase. Arch. Biochem. Biophys. 421, 135–142 (2004).
Birolo, G. et al. Protein stability perturbation contributes to the lack of operate in haploinsufficient genes. Entrance. Mol. Biosci. 8, 10 (2021).
Veldhuizen, E. J. A. et al. Regular-state kinetics and inhibition of anaerobically purified human homogentisate 1,2-dioxygenase. Biochem. J. 386, 305–314 (2005).
Lin, B. & Tao, Y. Complete-cell biocatalysts by design. Microb. Cell Truth. 16, 106 (2017).
Baneyx, F. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 10, 411–421 (1999).
Schein, C. H. Manufacturing of soluble recombinant proteins in micro organism. Bio/Technol. 7, 1141–1149 (1989).
Feller, G., Le Bussy, O. & Gerday, C. Expression of psychrophilic genes in mesophilic hosts: Evaluation of the folding state of a recombinant α-amylase. Appl. Environ. Microbiol. 64, 1163 (1998).
Shaw, M. Okay. & Ingraham, J. L. Synthesis of macromolecules by Escherichia coli close to the minimal temperature for progress. J. Bacteriol. 94, 157–164 (1967).
Broeze, R. J., Solomon, C. J. & Pope, D. H. Results of low temperature on in vivo and in vitro protein synthesis in Escherichia coli and Pseudomonas fluorescens. J. Bacteriol. 134, 861 (1978).
Tissue expression of HGD—Abstract—The human protein atlas. Out there at: https://www.proteinatlas.org/ENSG00000113924-HGD/tissue. Accessed: tenth Might 2022
Pollak, M. R. et al. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat. Genet. 5, 201–204 (1993).
Janocha, S. et al. The human gene for alkaptonuria (AKU) maps to chromosome 3q. Genomics 19, 5–8 (1994).
Ng, P. C. & Henikoff, S. Predicting the results of amino acid substitutions on protein operate. Annu. Rev. Genomics Hum. Genet. 7, 61–80 (2006).
Singh, A., Upadhyay, V., Upadhyay, A. Okay., Singh, S. M. & Panda, A. Okay. Protein restoration from inclusion our bodies of Escherichia coli utilizing delicate solubilization course of. Microb. Cell Truth. 14, 1–10 (2015).
Eiberle, M. Okay. & Jungbauer, A. Technical refolding of proteins: Do we’ve freedom to function?. Biotechnol. J. 5, 547–559 (2010).
Mizutani, H. et al. REFOLDdb: A brand new and sustainable gateway to experimental protocols for protein refolding. BMC Struct. Biol. 17, 1–8 (2017).
Colleen, Okay. & Gage, M. J. Protein unfolding: Denaturant vs. Power. Biomedicines 9, 1395 (2021).
Chai, S. C., Goktug, A. N. & Chen, T. Drug Discovery and Improvement—From Molecules to Medication. Assay Validation in Excessive-throughput Screening—From Idea to Validation (InTech, 2015). https://doi.org/10.5772/59765
Zhang, J. H., Chung, T. D. Y. & Oldenburg, Okay. R. A easy statistical parameter to be used in analysis and validation of excessive throughput screening assays. J. Biomol. Display screen. 4, 67–73 (1999).
